Penn Center for AIDS Research

恒虚警概述 摘要 宾夕法尼亚大学艾滋病研究中心(CFAR)的这份竞争性续签申请建立在 动态的科学领导、组织结构、资源和基础设施方面的出色记录 推动了整个宾夕法尼亚大学儿童综合校园内的艾滋病毒/艾滋病研究 费城医院和维斯塔尔研究所。CFAR的使命是催化尖端科学和 通过个人研究人员无法实现的活动为艾滋病研究企业增加价值 或研究项目。该中心由来自我们3个机构的250名成员组成，其中包括12个机构中的11个 宾夕法尼亚大学医学院和17个系内的主要合作伙伴。CFAR的成功 在过去的5年里，NIH为艾滋病提供了2亿美元的资金，这是艾滋病方面的主要发现 研究重点领域包括艾滋病毒治疗、疫苗开发、免疫蓄水池、生物行为 预防和参与护理、艾滋病毒共感染/共病和其他领域，以及3个跨学科领域 具有重大影响的科学工作组，包括资助马丁·德莱尼合作实验室。 展望未来，全面的战略规划进程使我们细化了CFAR的优先事项、核心活动、 和核心领导力，以利用新的专业知识和培养新的研究领导者，并保持领先地位 专注于我们的SWG。宾夕法尼亚大学CFAR现在处于有利地位，可以应对未来5年的关键挑战 好几年了。我们的CFAR最近设立了两个新的SWG(“减少艾滋病毒差距的技术”和“艾滋病毒 水库和组织免疫学“)已经取得重大影响的发现，并将进行 前进到下一个周期。CFAR支持一个开发核心和7个共享资源核心(临床、 病毒与水库，免疫学，预防科学与社区推广，生物统计与数据科学， 非人灵长类和国际)，为研究任务提供必要的支持。CFAR是由 由罗纳德·科尔曼博士(董事)和罗伯特·格罗斯(联席董事)主持，由执行委员会管理 内部咨询委员会、外部咨询委员会和社区咨询委员会的投入。 宾夕法尼亚大学CFAR有4个高度关联的具体目标，使其能够实现其使命：(1)提供 科学和行政领导能力和试点资金，以促进创新、跨学科研究， 将为艾滋病危机带来新的知识和解决方案；(2)吸引、培训、指导和支持下一个 一代艾滋病毒/艾滋病研究人员确保前瞻性的科学进步，吸引非艾滋病研究人员 进入具有交叉学科专业知识的领域，并推出下一代研究领军人物； (3)支持、监控和持续发展一套高效、动态和创新的共享资源核心 两者都支持艾滋病毒/艾滋病调查人员，并通过开发和传播 转化科学能力的创新技术；以及；(4)通过内部和外部合作促进科学和协同 校园、地方、国家和国际伙伴关系、社区参与和能力建设。

CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the University of Pennsylvania, Children's Hospital of Philadelphia & the Wistar Institute. The CFAR's mission is to catalyze cutting-edge science and add value to the AIDS research enterprise through activities that could not be achieved by individual investigators or research projects. The Center is comprised of 250 members from our 3 institutions, including 11 of the 12 Penn schools and 17 departments within the School of Medicine, and key partners. The success of the CFAR in the last 5 years is reflected in >$200M in AIDS-related NIH funding over that time, key discoveries in AIDS research priority areas including HIV cure, vaccine development, immune reservoirs, bio-behavioral prevention & engagement in care, HIV coinfections/comorbidities & other areas, and 3 interdisciplinary Scientific Working Groups with high impact outcomes including funding of a Martin Delaney Collaboratory. Looking ahead, a comprehensive strategic planning process has led us to refine CFAR priorities, Core activities, and Core leadership to leverage new expertise and cultivate new research leaders, and maintain a cutting-edge focus for our SWGs. The Penn CFAR is now well-positioned to address critical challenges during the next 5 years. Our CFAR recently established two new SWGs (“Technology to Reduce HIV Disparities” & “HIV Reservoirs & Tissue Immunology”) that have already achieved high impact discoveries and will be carried forward to the next cycle. The CFAR supports a Developmental Core and 7 Shared Resource Cores (Clinical, Virus & Reservoirs, Immunology, Prevention Science & Community Outreach, Biostatistics & Data Science, Nonhuman Primate, and International) that provide essential support for the research mission. The CFAR is led by Drs. Ronald Collman (Director) and Robert Gross (Co-Director) and governed by an Executive Committee with input from an Internal Advisory Board, External Advisory Committee and Community Advisory Board. The Penn CFAR has 4 highly inter-linked Specific Aims that enable it to achieve its mission: (1) Provide scientific and administrative leadership and pilot funding to catalyze innovative, interdisciplinary research that will lead to new knowledge and solutions for the AIDS crisis; (2) Attract, train, mentor and support the next generation of HIV/AIDS researchers to ensure forward-looking scientific progress, draw non-AIDS investigators into the field with cross-cutting interdisciplinary expertise, and launch the next generation of research leaders; (3) Support, monitor and continually evolve a set of efficient, dynamic & innovative Shared Resource Cores that both support HIV/AIDS investigators and lead the research agenda through development & dissemination of innovative technology that transforms scientific capacity, and; (4) Advance science and synergy through intra- campus, local, national & international partnerships, community engagement and capacity building.